Ex­clu­sive: Kimia Ther­a­peu­tics se­cures $55M to su­per­charge co-founder’s plat­form, cre­ate ‘next-gen­er­a­tion Car­mot’

Stig Hansen and his team are look­ing to repli­cate the suc­cess they had with Car­mot Ther­a­peu­tics, but un­der a dif­fer­ent name with the same mean­ing in an­oth­er lan­guage and a “su­per­charged” ap­proach to their drug dis­cov­ery plat­form.

Hansen spun out Kimia Ther­a­peu­tics and brought a hand­ful of em­ploy­ees with him in Jan­u­ary af­ter co-found­ing and lead­ing Car­mot for near­ly 15 years. Car­mot’s plat­form helped lay the foun­da­tion to de­vel­op Am­gen’s can­cer drug Lumakras, and then the com­pa­ny mold­ed its in­ter­nal pipeline in­to clin­i­cal-stage obe­si­ty and di­a­betes drug can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER